Key Highlights
- Tempus AI introduces a new program to surface patients likely to benefit from HER2 testing.
- The program leverages AI algorithms as part of the Tempus Next platform.
- Focus on identifying care gaps and providing actionable insights for clinicians.
- Initial deployment at select pilot sites with RNA sequencing assay integration.
Source: Business Wire
Notable Quote
- “Next demonstrates how the practical application of AI can have a positive impact on everyday clinical care by meeting the needs of patients as treatment choices become increasingly complex. This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep connectivity with providers, comprehensive testing portfolio, and AI-enabled data analytics to deliver a tool that physicians can use in real-time to provide patients with the most up-to-date, guideline-directed care.” — Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus
SoHC's Take
Tempus AI’s launch of this new program marks a significant advancement in precision medicine. By leveraging AI to identify patients who are more likely to test positive for actionable biomarkers such as HER2, Tempus is equipping clinicians with critical insights that can lead to more timely and accurate treatment decisions. This integration of AI with RNA sequencing assays and the Tempus Next platform showcases the practical benefits of AI in healthcare, highlighting Tempus’ commitment to improving patient outcomes through innovative technology. As treatment options become more complex, tools like these will be invaluable in ensuring patients receive the most effective, guideline-directed care.
